SpringWorks Therapeutics, Inc. (SWTX)
Automate Your Wheel Strategy on SWTX
With Tiblio's Option Bot, you can configure your own wheel strategy including SWTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SWTX
- Rev/Share 2.9334
- Book/Share 5.5738
- PB 8.4252
- Debt/Equity 0.0177
- CurrentRatio 4.3312
- ROIC -0.6232
- MktCap 3538389040.0
- FreeCF/Share -2.328
- PFCF -20.2968
- PE -13.8486
- Debt/Assets 0.0146
- DivYield 0
- ROE -0.511
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
Read More
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –
Read More
Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of SpringWorks will receive only $47 per share in cash, which represents an equity value of.
Read More
Merck KGaA swoops for US group SpringWorks in $3.4bn deal
Published: April 28, 2025 by: Proactive Investors
Sentiment: Positive
Germany's Merck KGaA has agreed to acquire US biotech firm SpringWorks Therapeutics for $3.9 billion in cash. The deal, announced on Monday, values SpringWorks at $47 a share and reflects an enterprise value of $3.4 billion after accounting for the company's cash reserves.
Read More
Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal
Published: April 28, 2025 by: WSJ
Sentiment: Positive
The deal to acquire the U.S. biopharmaceutical company confirms an earlier report in The Wall Street Journal.
Read More
Germany's Merck KGaA in $3.9 bln deal to acquire US biotech firm SpringWorks
Published: April 28, 2025 by: Reuters
Sentiment: Positive
German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech firm SpringWorks Therapeutics for an equity value of $3.9 billion to boost its cancer drug business.
Read More
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business – – SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas – – Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany's Healthcare business in …
Read More
Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a Stamford, Connecticut-based commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the companies have entered into a definitive agreement for Merck KGaA, Darmstadt, Germany, to acquire SpringWorks. The purchase price of $47 per share in cash represents an equity value of appr.
Read More
SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock?
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
SpringWorks Therapeutics (SWTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Positive
SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo's revenues alone reached $172 million in 2024, supported by orphan drug designations in the US and EU. Similarly, Gomekli is the first FDA-approved MEK inhibitor for NF1‑plexiform neurofibromas, which targets both adults and children.
Read More
SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
Read More
SpringWorks Therapeutics (SWTX) Reports Q4 Loss, Tops Revenue Estimates
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Negative
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.44 per share a year ago.
Read More
SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over
Published: February 19, 2025 by: PRNewsWire
Sentiment: Neutral
- Educational campaign aims to raise awareness and drive conversation about desmoid tumors, the devastating impact they have on patients' lives - STAMFORD, Conn. , Feb. 19, 2025 /PRNewswire/ -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and Jennifer Fisher, jewelry designer and desmoid tumor patient advocate, are collaborating to increase understanding of desmoid tumors as well as to encourage patients to find a specialist, like an oncologist with experience treating desmoid tumors who can discuss available treatment options to manage their desmoid tumor.
Read More
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics
Published: February 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOUISVILLE, Ky., Feb. 17, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent specialty pharmacy, has been selected as a national pharmacy partner by SpringWorks Therapeutics, Inc. for GOMEKLI (mirdametinib). The Food & Drug Administration approved GOMEKLI for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.1
Read More
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9 https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86b https://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4944-8736-24cb19a5dec9 https://www.globenewswire.com/NewsRoom/AttachmentNg/072d748b-3237-48ad-8d83-1c6c23dda65f STAMFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that …
Read More
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9 https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86b https://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4944-8736-24cb19a5dec9 https://www.globenewswire.com/NewsRoom/AttachmentNg/072d748b-3237-48ad-8d83-1c6c23dda65f STAMFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that …
Read More
About SpringWorks Therapeutics, Inc. (SWTX)
- IPO Date 2019-09-13
- Website https://www.springworkstx.com
- Industry Biotechnology
- CEO Mr. Saqib Islam J.D.
- Employees 368